Ixabepilone (Ixempra) | AETNA Coverage Update

Summary: Aetna modified CPB 0869 covering ixabepilone (Ixempra) coverage policy, effective April 8, 2026. Here's what billing teams need to know before claims go out the door.

Aetna, a CVS Health company, updated CPB 0869, which governs ixabepilone (Ixempra) reimbursement for oncology practices and infusion centers billing this chemotherapy agent. The policy does not list specific CPT or HCPCS codes in the available data — we'll cover what that means for your charge capture below. If your practice bills ixabepilone for breast cancer or other oncology indications, this policy change is worth a close read before April 8, 2026.

Quick-Reference Table

Aetna Ixabepilone Coverage Criteria and Medical Necessity Requirements 2026

CPB 0869 is Aetna's clinical policy bulletin governing coverage of ixabepilone (Ixempra), an epothilone B analog used primarily in metastatic or locally advanced breast cancer. The drug is typically reserved for patients who have failed anthracycline- and taxane-based regimens — meaning it shows up later in treatment lines, where prior authorization scrutiny tends to be highest.

Aetna's ixabepilone coverage policy has always leaned heavily on FDA-approved indications and NCCN guideline alignment. Modifications to CPB 0869 typically tighten or clarify the criteria around treatment history, combination use with capecitabine, and monotherapy eligibility. If your prior authorization requests have been hitting walls recently, this update is likely why.

The available policy data for this modification does not include a full text summary. That's not unusual for mid-cycle updates, but it does create a real problem for billing teams. You need to pull the current version of CPB 0869 directly from Aetna's clinical policy library and compare it line by line against what your team was working from before April 8, 2026.

Medical necessity documentation for ixabepilone claims is non-negotiable with Aetna. You need clear chart support showing prior treatment failure, the specific line of therapy, and the oncologist's rationale for ixabepilone over alternatives. If that documentation doesn't align exactly with CPB 0869's updated criteria, you will get a claim denial — and ixabepilone's per-dose cost makes those denials expensive.

Prior authorization is required for ixabepilone under Aetna plans. That has not changed. What may have changed — based on the modification pattern for oncology drug policies in 2026 — is the specific criteria Aetna requires to approve that prior auth. Check the updated policy before you submit your next authorization request.

Aetna Ixabepilone Exclusions and Non-Covered Indications

Ixabepilone has a narrow FDA-approved label. Aetna's coverage policy reflects that narrowness and has historically excluded uses outside metastatic or locally advanced breast cancer that have progressed through standard regimens.

Off-label use is where most claim denials happen. Ixabepilone billing for indications outside Aetna's approved list — including experimental combinations or earlier treatment lines than the policy allows — will almost certainly be denied. The real issue here is that oncologists sometimes use ixabepilone based on emerging trial data or NCCN category 2B designations. Aetna's coverage policy may not have caught up with those uses, and in many cases it won't cover them at all.

If your practice is billing ixabepilone for any indication beyond the core breast cancer indication, talk to your compliance officer before April 8, 2026. This is a high-cost drug. A denial on a multi-infusion course isn't a minor AR problem — it's a significant write-off.

Coverage Indications at a Glance

The full policy text for this modification is not available in the source data. The table below reflects Aetna's established coverage framework for ixabepilone based on CPB 0869 and the FDA label. Confirm every row against the updated policy before using this for claim decisions.

Aetna Ixabepilone Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Ixabepilone Under CPB 0869

The policy data available for this modification does not include specific CPT, HCPCS, or ICD-10 codes. This is an important gap. Do not assume the codes you are currently using are correct without verifying against the updated CPB 0869 text.

That said, ixabepilone billing typically involves drug administration codes alongside the drug itself. The specific HCPCS code for ixabepilone is an established part of oncology billing guidelines, and it must appear on your claims with supporting diagnosis codes that align with Aetna's approved indications.

What to do right now: Pull the current CPB 0869 from Aetna's policy library and confirm which HCPCS J-codes and administration CPT codes the policy references. Then confirm that your charge capture uses those exact codes. A code mismatch on a high-cost oncology drug claim is a fast way to trigger a denial or a post-payment audit.

If your practice management system has a code crosswalk for ixabepilone claims, verify it against the April 8, 2026 version of CPB 0869. Do not rely on a crosswalk that hasn't been updated since the last CPB 0869 revision.